KR20180114499A - in situ Hydrogel Forming Powder Composition for Wound Healing, and Method for Preparing thereof - Google Patents

Abstract

The present invention relates to a powder composition for treating wound, containing S-nitrosoglutathione (GSNO), an alginate salt, pectin, and polyethylene glycol (PEG) as active ingredients. The present invention further relates to a production method thereof. According to the present invention, the composition uses GSNO and an in-situ hydrogel formation system based on alginate capable of adequately regulating drug release. The composition has advantages of acid agents and film agents, increases stability of preparations when stored, and also provides moisturized environment or covers up the wound as the composition quickly changes to gel when applied to the wound. In addition, bacteria present in exudative wounds are effectively removed, and wound healing can be facilitated as cell differentiation and collagen synthesis are promoted.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a powder composition for wound healing,

The present invention relates to a powder composition for wound healing which is hydrogelized when applied to a wound, and a method for producing the same.

The skin that surrounds our body is exposed to many dangerous physical injuries in our daily lives. Therefore, there are a lot of factors around us, such as mechanical damage, bruises, burns, etc., of the skin. A wound refers to a state in which the anatomical continuity of a human tissue has lost its original continuity due to external action. For example, our skin consists of epidermis, dermis, and subcutaneous fat, and it is said that the loss of continuity of epidermis, dermis, subcutaneous fat, etc.

Generally, dressing is used to effectively treat skin wounds such as wound, trauma, and the like. The characteristics of dressing for wound healing should be as follows: ability to maintain proper moisture in contact with wound, ability to control wound excretion, ease of adhesion and removal of dressing to wound, air and water vapor permeability between external wound area, , Resistance to invasion of bacteria, non-toxicity to the human body, and excellent mechanical properties are required.

Currently, the most popular methods of healing wounds include applying ointment. Madecasol (Dongkuk Pharm), Sentica (Samjin Pharm) and Tinadex (Chong Kun Dang) are the most commonly used skin wound healing stimulants.

The nitric oxide-releasing film containing S-nitrosoglutathione (GSNO), which is a nitrogen oxide donor spontaneously formed in the human body, not only has mechanical properties applicable to the human body but also gradually oxidizes The film can be useful for wound healing since it releases nitrogen and inhibits pathogens that are the main cause of wound infections and can treat wounds quickly.

However, due to the nature of the film formulation, there are limitations in application to wounds resulting from exudates, wounds on a wide range of wounds or body parts with many movements. In addition, there is a limit in that the stability of GSNO can not be secured under the storage conditions such as refrigeration and room temperature outside the -20 ° C due to a manufacturing process problem.

In addition, hydrogel-type formulations may be more useful than film formulations in the case of wounds with large areas of wounds or movement, but most of the nitric oxide donors, including S-nitroglycerin, , It is very difficult to secure the stability of the preparation for film-form preparation. On the other hand, in the case of powder, the stability is excellent, but it is not possible to provide a wet environment at the wound site, and the emission pattern of NO is abruptly formed, which makes it difficult to maintain the concentration for maintaining the therapeutic effect for a long time.

Korean Registered Patent No. 10-0445146 (registered August 10, 2004).

It is an object of the present invention to provide a method of hydrogeling (S-Nitrosoglutathione) which is capable of rapidly absorbing exudate from a wound site and converting it into a gel form, which is a nitric oxide donor S- And to provide a powder composition for wound healing.

Another object of the present invention is to provide a method for producing a powder composition for wound healing which is quickly hydrogelized upon application to a wound.

In order to achieve the above object, the present invention provides a powder composition for wound treatment comprising S-Nitrosoglutathione (GSNO), alginate salt, pectin and polyethylene glycol (PEG) do.

In order to achieve the above other objects, the present invention provides a method for producing a granulated product, comprising: (1) pulverizing GSNO, alginate salt, pectin and PEG in powder form, respectively; (2) mixing all the pulverized products produced in the step (1); And (3) passing the mixture prepared in the step (2) through a sieve.

The present invention relates to a powder composition for wound healing which is hydrogelized when applied to a wound, and the powder composition of the present invention is hydrogelized to effectively treat a wound area of a larger area than a film-shaped preparation, There are exudates such as pressure ulcers and burns, which are more susceptible to infections and have a wider range of wounds than those of conventional commercialized products. All of the materials used are biocompatible, In addition, the production process is simple and easy to mass-produce, and is also stable at room temperature when stored in a sealed container.

FIG. 1 shows water absorption and morphological changes of a wound treatment powder composition containing nitrogen oxide which is hydrogelized when applied to a wound of the present invention.
2 shows the storage stability of the powder composition of the present invention.
FIG. 3 shows the results of an experiment of NO release according to the degree of water absorption of the powder composition of the present invention.
FIG. 4 shows the results of an in vitro antibacterial test of the powder composition of the present invention.
5 shows the results of the antibacterial activity test using the confocal laser fluorescence microscopy of the powder composition of the present invention.
6 is a Pseudomonas aeruginosa of a powder composition of this invention (Pseudomonas aeruginosa ) infected animal models.
FIG. 7 shows the results of an experiment to determine the number of bacteria in the wound in an in vivo animal model.
FIG. 8 shows the result of Twot's gram staining (normal skin (A), untreated group (B), group C), powder carrier treated group (D) , The powder composition treatment group (E) of the present invention).
(A, B, C and D show H & E staining and E, F, G and H show Masson's trichrome staining technique. E is a normal tissue, B and F are untreated groups, C and G are groups treated only with a powder carrier, D and H are groups treated with the powder composition of the present invention, E: epidermis, F: Fibrous tissue G: granulation tissue H: hair follicle I: immune cells M: muscle.
FIG. 10 shows the results of confirming the uniformity of the GSNO content of the powder of the composition prepared by the method including the pulverization process.
FIG. 11 shows the results of comparing the therapeutic effects according to the content of alginate salt in the composition powder of the present invention.
FIG. 12 shows the gelation formation test results according to the presence or absence of pectin and PEG in the composition powder of the present invention.

Hereinafter, the present invention will be described in more detail.

The inventors of the present invention have found that when GSNO and alginate salts are used as a base, they are excellent in promoting wound healing and can be rapidly converted into a gel form by effectively absorbing exudates from wound sites due to their antibacterial effect. As a result, The present invention has been completed based on the finding that a powdery preparation can be used for treating wounds having a large area.

Accordingly, the present invention provides a powder composition for treating wound comprising S-Nitrosoglutathione (GSNO), alginate salt, pectin and polyethylene glycol (PEG) as an active ingredient.

Using alginate as a gelling agent, GSNO having a wound-promoting effect and antimicrobial effect absorbs the exudate from the wound site and can quickly change into a gel form, and hydrogel formation in situ It is possible.

GSNO, which is a major active ingredient in the powder composition, is a nitric oxide donor which is also present in the body. It is involved in cell differentiation and collagen synthesis process by nitrogen oxide (NO) generated by decomposition and promotes it and helps recovery of the wound. In addition, oxidative stress caused by oxidized nitrogen has an antimicrobial effect, and this mechanism is suitable for use in skin wound infections because it has almost no resistance and exhibits an antibacterial effect without distinguishing between gram-negative and positive.

In one embodiment of the present invention, 2 parts by weight to 10 parts by weight of GSNO, 10 to 40 parts by weight of alginate salt, 5 to 20 parts by weight of pectin and 50 parts by weight of PEG are added to 100 parts by weight of the powder composition, 80 wt.%. If it is included in the above-mentioned numerical range, it is preferable that denaturation into a uniform and strong gel is performed rapidly at the wound site and the wound healing effect is maximized.

More preferably, the GSNO: alginate salt: pectin: PEG may be included in a weight ratio of 4: 21: 11: 64.

The powder composition can be modified into a hydrogel form within 1 minute to 3 minutes at the wound site. The powder composition according to the present invention solves the problem in powder form or film form, .

Particularly, the powder composition can be used for treating wound healing by releasing nitrogen oxide (NO) from the wound site, or for treating a wound of any one or more of Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus (MRSA) In the present invention, the powder composition of the present invention is improved in the release of nitrogen monoxide, and the MRSA, which is the most problematic Gram- And gram-negative bacteria, P. aeruginosa Of the bacteria were found to be more than 99.99%.

The wound can be any one or more selected from abrasions, lacerations, burns, stabbing, raising, plating, penetrating, and upper left, but is not limited thereto.

Further, the present invention provides a method for producing a granulated product comprising: (1) pulverizing GSNO, alginate salt, pectin and PEG in powder form, respectively; (2) mixing all the pulverized products produced in the step (1); And (3) passing the mixture prepared in the step (2) through a sieve.

2 to 10 parts by weight of GSNO, 10 to 40 parts by weight of alginate salt, 5 to 20 parts by weight of pectin, and 50 to 50 parts by weight of PEG 50, based on 100 parts by weight of the powder composition in the above steps (1) to (3) To 80 parts by weight. When the powder composition is contained in such a range, it is possible to produce a powder composition which is rapidly denatured to a uniform and durable gel at the wound site and maximizes the wound healing effect.

In the step (3), the sieve may be a porous structure having an average diameter of 80 [mu] m to 100 [mu] m, but is not limited thereto.

More specifically, in step (3), the powdered wound treatment powder composition may contain GSNO: alginate salt: pectin: PEG in a weight ratio of 4: 21: 11: 64.

BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the present invention will be described in detail with reference to the following examples. It is to be understood that both the foregoing description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed. no.

< Example  1> Preparation of Powder Composition for Wound Treatment according to the Present Invention

GSNO, sodium alginate, pectin and PEG (MW: 8000) were first pulverized to pass through the No. 170 standard (the average diameter of the pores was 90 탆) in order to prepare the powder composition for wound treatment according to the present invention. Thereafter, GSNO: alginate salt: pectin: PEG was mixed at a weight ratio of 4: 21: 11: 64, and the mixture was passed through a No. 170 sieve to prepare a powder composition for wound treatment according to the present invention. As a control, a gelling powder (Comparative Example 1) prepared by mixing GSNO, sodium alginate, pectin and PEG (MW: 8000) without grinding at the same weight ratio as above was used. In the case of a carrier not containing GSNO , Sodium alginate: pectin: PEG in a weight ratio of 2: 1: 6 was used.

<Experimental Example 1> Analysis of moisture absorption and morphological change

The morphological changes of the powder composition prepared in Example 1 over time were confirmed through water absorption experiments. Specifically, the in vitro test method was as follows: First, the cellulose membrane was brought into contact with a simulated wound fluid (SWF) simulating a wound exudate. Then, 40 mg of the powder composition prepared in Example 1 was dissolved in cellulose And distributed evenly over the membrane. At this time, since water molecules are diffused over the cellulose membrane and absorbed into the powder composition, photographs are taken at designated time intervals and the weight thereof is measured to measure the amount of absorbed fluid (exudate).

In vivo experiments were as follows: Seven-week-old ICR mice were anesthetized and the hairs on the dorsal side were removed and a full-thickness wound was created with an 8 mm biopsy punch. 40 mg of the powder composition prepared in Example 1 was evenly sprayed thereon, and a photograph was taken at a designated time.

As a result, as shown in FIG. 1, it was confirmed that the powder composition prepared in Example 1 had a capability of absorbing up to 350% of water and rapidly changed into a gel form (FIG. 1 (A) FIG. 1 (B): Changes in the state of the powder when the powder was treated with a full thickness excision wound in an in vivo mouse model. 1 (C): Measured water absorption ability of powder).

<Experimental Example 2> Storage stability analysis

The storage stability of the powder composition prepared in Example 1 was analyzed. Specific experimental methods were as follows: 10 mg of the powder composition prepared in Example 1 was placed in a microtube, and then placed in a 4 ° C refrigerator and a 37 ° C incubator. After that, 3 microtubes were taken out at a constant time and dissolved in water, and the absorbance at 335 nm was measured with an ultraviolet absorption spectrophotometer to quantitatively compare the amount of GSNO.

As a result, as shown in FIG. 2, significant decomposition of GSNO in the powder composition was not observed even at the storage conditions of 4 ° C. and 37 ° C. for 140 days. From this point of view, It is possible to store without fear of decomposition of the drug.

<Experimental Example 3> Experimental analysis of NO emission according to degree of water absorption of GNSO

The powder composition prepared in Example 1 was examined for the amount of GNSO released depending on the degree of water absorption. Specifically, 50 mg of the powder composition prepared in Example 1 was uniformly dispersed on a bottom surface of a 2-ml microtube which had a flat bottom, ), The most absorbed state (350%), and the amount of SWF (500%) that was exposed to a larger amount of exudate than the absorbable amount. After that, 3 microtubes were placed in a 37 ° C incubator and the contents of residual microspheres were measured and analyzed by using an external spectrophotometer.

As a result, as shown in FIG. 3, when the powder is exposed to a small amount of moisture, exposed to a large amount of moisture, and exposed to moisture in a moisture environment of a maximum absorption point or more, Respectively.

<Experimental Example 4> In vitro antibacterial test

The powder composition prepared in Example 1 was subjected to an in vitro antibacterial test. Specifically, the following experimental methods were carried out: After culturing for 12 hours, P. aeruginosa (purchased from PAO1, purchased from KCTC) and MRSA (purchased from USA 300, ATCC) 10 ⁸ CFU / ml of the microorganism was added to the powder composition for 24 hours, and the CFU was measured and compared. The bacterium exposed to the powder composition prepared in Example 1 for 24 hours was stained using a Baclight live / dead kit and photographed with a confocal laser fluorescence microscope.

As a result, as shown in FIG. 4, it was confirmed that 99.99% or more of bacteria were reduced in both P. aeruginosa and MRSA bacteria in vitro.

Also, as shown in Fig. 5, almost all the points in the group treated with the composition appeared red, indicating that most of the bacteria died (green fluorescence indicates living bacteria and red fluorescence indicates dead bacteria) .

&Lt; Experimental Example 5 >

The powder composition prepared in Example 1 was tested for wound recovery ability in a bacterial infected ICR mouse model. Specifically, the following experiment was carried out: Six weeks old ICR mice were purchased, adapted for 1 week, then anesthetized and hair removed. An 8-mm biopsy punch was used to create a full-thickness wound on the back, 10 ⁹ CFU of P. aeruginosa was added per wound and the wound was sealed and left for 2 days to create an infected whole wound. Thereafter, the powder composition prepared in Example 1, the powder composition without powdery GSNO (powder carrier), and the non-treated group were treated every two days, and the photographs were taken every time, and the sizes were compared and analyzed Respectively.

As a result, as shown in FIG. 6, it was confirmed that the size of the wound was remarkably decreased with time, and it was confirmed that the group treated with the powder had a remarkably superior wound than the group treated with only the powder- Size reduction effect.

&Lt; Experimental Example 6 > In vivo determination of mycobacteria and Gram staining of Twort

In the powder composition prepared in Example 1, the number of bacteria in the wound in the mouse model was determined. At this time, the following experiment was carried out: 6 weeks old ICR mice were purchased, adapted for 1 week, then anesthetized and hair removed. An 8-mm biopsy punch was used to create a full-thickness wound on the back, 10 ⁹ CFU of P. aeruginosa was added per wound and the wound was sealed and left for 2 days to create an infected whole wound. Thereafter, the powder composition prepared in Example 1, the powder composition without powdery GSNO (powder carrier), and the untreated group were divided into three groups, and three mice were euthanized each day to remove the wound area After finely crushed and diluted, only P. aeruginosa was cultured in selectively grown cetrimide medium, and CFU was measured.

Also, Twort's Gram stain was performed as follows: On the 14th day of the experiment, the animal was euthanized, and the injured area was collected and made into a paraffin block. The block was cut to a thickness of 5 μm and attached on a slide glass and dried in an oven at 37 ° C for 12 hours. Paraffin was removed using xylene, and 100% ethanol and 95% ethanol were added, respectively, followed by washing with distilled water. After primary dyeing with crystal violet, secondary dyeing with natural red and fast green solution, the mounting medium was put through the transparent process with xylene and the cover glass was covered. Lastly, P. aeruginosa with a red length of about 1 μm was observed and photographed at a magnification of 1000 times magnified using an optical microscope.

As a result, as shown in Fig. 7, P. aeruginosa When the amount of microorganisms present in the wound was measured in the infected ICR mouse model, the amount of microorganisms in the powder composition-treated group was remarkably reduced, indicating that the powder composition according to the present invention was able to effectively remove microorganisms in the wound area .

In addition, as shown in FIG. 8 showing the result of the bacterium identification test (Twort's gram staining) on the wound surface at the 14th day after the initiation of treatment, the wound area on the day 14 after the initiation of treatment was histologically observed P. aeruginosa Through the tissue staining technique to visualize the presence of bacteria, a large number of bacteria could be visually observed in the untreated group, but there was only a small number of bacteria that could not be detected in the group treated with the powder composition ( Treated group (A), untreated group (B, C), powder carrier treated group (D), powder composition (E) treated group of the present invention).

&Lt; Experimental Example 7 >

The powder composition prepared in Example 1 was subjected to masson's trichrome staining for hematoxylin & eosin staining (H & E staining) and collagen amount confirmation for tissue confirmation, Respectively. Specifically, the method was performed as follows: Animals were euthanized on the 14th day of the experiment, and the injured area was collected and made into a paraffin block. It was then cut into 5-μm thick slices on a slide glass and dried in an oven at 37 ° C for 12 hours. Paraffin was removed using xylene, 100% ethanol and 95% ethanol were added, respectively, and washed with distilled water. In the case of H & E staining, hematoxylin and eosin were stained in turn. In the case of Mathon's trichrome staining, staining was performed according to the staining procedure provided by the seller (ABCAM). The tissues were then compared and observed at a magnification of 200 times using an optical microscope.

As a result, referring to FIG. 9A to FIG. D, when the powder composition was treated, it was found that the powder composition recovered to a level close to normal tissue as compared with the non-treated group or the powder group treated only with the powder carrier. In addition, referring to FIGS. 9E to 9H, a larger amount of collagen was observed in the group treated with the powder composition than in the other two groups.

<Experimental Example 8> Comparison of Powder Particle Characteristics According to Experimental Methods

The powder composition prepared in Example 1 and the comparative example 1 prepared without the pulverization process were tested for uniformity of contents. That is, the GSNO content was measured by randomly sampling 10 powder samples from each powder. At this time, the weight of powder of about 10 mg was measured, and after dissolving in water, the absorbance was measured at 335 nm using an ultraviolet spectrophotometer, and the content of GSNO was measured and compared. In addition, the ratio of the housing ratio was calculated by dividing the tap density and the bulk density.

As a result, as shown in FIG. 10, it was confirmed that the powder composition of Example 1 after the pulverization process was able to produce a more uniformly distributed preparation of GNSO, and also the powder ratio , It is confirmed that the phenomenon of flowing down before the powder changes into gel when applied to actual wound can be further reduced.

Experimental Example 9 Comparison of gel formation time with other gelling agents

A powder carrier composition containing various gelling agents was prepared in the same manner as in Example 1 except that GSNO was not mixed in order to confirm whether or not there was a difference in gel forming ability when using other gelling agent instead of alginate . Specifically, as a comparative example, hyaluronic acid (Hyaluronate), carrageenan, poloxamer, gelatin, guar gum, CMC-Na or chitosan were used instead of alginate as a gelling agent Comparative Examples 2 to 8 Powder carrier compositions were prepared. At this time, the content ratio of each composition was the gelling agent: pectin: PEG = 2: 1: 6 in the same manner as the excipient ratio of the powder composition of Example 1 except GSNO.

Then, 10 mg of each composition was placed in a 2 ml flat bottomed tube, 100 μl of PBS was dropped, and the time point of gelation was measured. At this time, when the tube was inverted and lightly knocked as a gel, the gel was not dropped more than 5 seconds and was attached to the tube.

As a result, in order to use as in situ hydrogel-forming powder, rapid gel-forming ability within 3 minutes is essential. As shown in Table 1 below, in case of the gelling agent except for alginate and hyaluronic acid, Or more, indicating that it is not suitable as a gelling agent for the in situ hydrogel-forming powder. That is, although alginate and hyaluronic acid showed in situ hydrogel formation phenomenon, hyaluronic acid showed a slower gelation rate than alginate, so that alginate was the most suitable gelling agent for rapid gel formation.

<Experimental Example 10> Comparison of therapeutic effect according to alginate content

In order to confirm whether the treatment effect is effective even when a low concentration of alginate is contained, a powder composition is prepared according to the preparation method described in Example 1, and the alginate content is set to 10% (based on the total weight) A powder containing 2% of GSNO and a powder containing 10% of GSNO were prepared. The ratio of GSNO: alginate salt: pectin: PEG was 2: 10: 5: 83 and 10: 10: 5: 75 as the content ratios. (GSNO: alginate salt: pectin: PEG: 4: 40: 20: 36) was prepared in the same manner as in Example 1, except that the amount of alginate And treated in a mouse animal model in the same manner as the powder composition.

At this time, specific experimental methods were as follows: 6 weeks old ICR mice were purchased and adapted for 1 week, then anesthesia and hairs were removed. The wound was created using a biopsy punch of 8 mm on the back, and the drug was treated with the drug and the GSNO-free carrier powder composition and the untreated group, and the photographs were taken every 2 days for comparison and analysis .

As a result, referring to FIG. 11A, in the case of the composition powder using alginate (2% and 10%) having a low content of less than 15%, the gel form could not be maintained due to insufficient absorption of the exudate, GSNO was easily removed, In particular, treatment with a mouse showed no significant therapeutic effect. On the other hand, referring to FIG. 11B, the powder composition containing 15 to 30% of alginate continuously absorbed exudates to maintain the gel shape, and released NO, showing a significant therapeutic effect, particularly in the mouse model. In addition, referring to FIG. 11C, when the alginate is contained at a too high ratio (more than 30%), the absorbency is too high to dry the wound area and the dressing is strongly clogged with the wound, Respectively.

<Experimental Example 11> Examination of the role of pectin and PEG

In order to confirm the role of pectin and PEG, alginate was fixed at 22 parts by weight and the amount of pectin and PEG was changed to experiment. That is, a powder composition was prepared according to the preparation method described in Example 1, except that 22 parts by weight of alginate and 77 parts by weight of pectin (alginate: pectin = 2: 7 ratio by weight) (Alginate: pectin: PEG = 2: 1: 6 weight ratio (weight ratio)) containing only 77 parts by weight of PEG (alginate: PEG = 2: 7 weight ratio) and 22 parts by weight of alginate, 11 parts by weight of pectin and 66 parts by weight of PEG ) Was contained, the gel-forming experiment was carried out after each powder of (C) was prepared. Specific methods were as follows: Each powder prepared was evenly dispersed into a small dish of 50 mg, and 1 ml of distilled water was evenly added to observe the shape of the formed gel.

As a result, as shown in Fig. 12, when no PEG was present (A), a phenomenon in which the powder particles were entangled with each other occurred, and a gel having a high viscosity was formed only at the portion where the powder was sprayed. One gel was formed but the strength of the gel was weak and the time until the gel did not completely flow was longer than when pectin was present. As in Example 1 of the present invention, it was confirmed that a gel was uniformly formed quickly and uniformly when all of alginate, pectin and PEG were contained (C).

From these experimental results, it was found that an excessive amount of pectin or PEG is not suitable for the formation of a homogeneous and durable gel, and the formulation containing 5 to 20 parts by weight of pectin and 50 to 80 parts by weight of PEG is suitable as an in situ hydrogel- Could know.

While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will appreciate that such specific embodiments are merely preferred embodiments and that the scope of the present invention is not limited thereby. Do. That is, the practical scope of the present invention is defined by the appended claims and their equivalents.

Claims (10)

A wound treatment powder composition comprising S-Nitrosoglutathione (GSNO), alginate salt, pectin and polyethylene glycol (PEG) as an active ingredient. 2. The process according to claim 1, wherein the powder composition comprises 2 to 10 parts by weight of GSNO, 10 to 40 parts by weight of alginate salt, 5 to 20 parts by weight of pectin and 50 to 80 parts by weight of PEG, Wherein the powdery composition is a powder. The wound dressing powder composition according to claim 1, wherein the GSNO: alginate salt: pectin: PEG is contained in a weight ratio of 4: 21: 11: 64. The powder composition for wound healing according to claim 1, wherein the powder composition is modified into a hydrogel form within 1 minute to 3 minutes at the wound site. 2. The powder composition for wound healing according to claim 1, wherein the powder composition is treated by releasing nitrogen oxides (NO) from the wound area. The method of claim 1, wherein the powder composition is selected from the group consisting of Pseudomonas aeruginosa , or methicillin-resistant Staphylococcus aureus . The present invention also provides a powder composition for wound healing, which comprises an antimicrobial activity against at least one microorganism selected from the group consisting of aeruginosa , methicillin-resistant Staphylococcus aureus , and methicillin-resistant Staphylococcus aureus . [Claim 2] The powder composition for treating wound healing according to claim 1, wherein the wound is at least one selected from the group consisting of abrasion, laceration, burn, swelling, raising, plating, penetration and sediment. (1) pulverizing GSNO, alginate salt, pectin and PEG in powder form, respectively;
(2) mixing all the pulverized products produced in the step (1); And
(3) passing the mixture prepared in the step (2) through a sieve. 9. The method according to claim 8, wherein, in steps (1) to (3), 2 to 10 parts by weight of GSNO, 10 to 40 parts by weight of alginate salt, 5 to 40 parts by weight of pectin, 20 to 50 parts by weight of PEG and 50 to 80 parts by weight of PEG. The wound treatment powder according to claim 8, wherein in the step (3), the powdered wound dressing composition comprises GSNO: alginate salt: pectin: PEG in a weight ratio of 4: 21: Composition.

Images